Startups
A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
The company’s proprietary CRISPR-Cas tech platform is used to selectively and precisely eradicate target bacterial, but still leave the patient’s microbial community alone.
No employees of GTx are expected to remain with the new company once the merger is complete. Oncternal will begin to trade on the Nasdaq under the ticker symbol ONCT.
For more than a year, it had no name other than “ABC,” the first letters of each company’s name. Now, more than a year later, the endeavor has an official name, Haven.
Beam Therapeutics is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019.
Glenmark Pharmaceuticals’ new innovation business has its chief executive officer. Alessandro Riva, head of oncology therapeutics and cell therapy at Gilead Sciences will take over the reins of the new innovation company as its CEO on April 2. Riva is the first named executive of the new company.
While real estate developers are building new spaces for life science companies in the Bay Area, startups are struggling to find space.
The company will focus on what are dubbed modifier genes. Essentially, two people with the same disease-causing genetic mutations often show varying degrees of illness, or in some cases, none at all.
Blackstone Life Sciences, a private investment firm, along with Novartis, launched Anthos Therapeutics with a $250 million investment. Anthos will be headquartered in Cambridge, Mass.
The San Francisco Business Times recently looked at top alumni from Bay Area incubators. Some of those companies are now brand-name companies like Uber and Reddit. Here’s a look at the biotech companies on their list.
PRESS RELEASES